CMML Leukemia: Symptoms, Diagnosis, and Treatment

Chronic myelomonocytic leukemia (CMML) is an uncommon blood cancer in which the bone marrow overproduces monocytes, a type of white blood cell involved in immune defense. It sits in an unusual spot between two broader categories of blood disorders, sharing features of both myelodysplastic syndromes (where blood cells form abnormally) and myeloproliferative neoplasms (where too many blood cells are produced). That dual nature makes CMML tricky to diagnose, challenging to classify, and harder to treat than many patients and even some clinicians expect.

What CMML Feels Like

CMML tends to creep up slowly. Many people have no symptoms at all when their blood counts first become abnormal, and the disease is discovered incidentally on routine lab work. When symptoms do appear, they usually stem from the downstream effects of disrupted blood cell production rather than from the leukemia cells themselves.

Fatigue is by far the most common complaint, driven largely by anemia. At the time of diagnosis, roughly four in ten patients have a hemoglobin level below 100 g/L, and about a quarter already need red blood cell transfusions.¹ Because monocyte counts are elevated, the immune system behaves erratically. Recurrent infections, fevers, night sweats, and unintended weight loss are common enough that some patients are initially worked up for infection or autoimmune disease rather than cancer.

An enlarged spleen is another hallmark, particularly in the proliferative form of the disease. The spleen can grow large enough to cause a dragging discomfort or early fullness after eating. Skin findings, including rashes, nodules, or gum swelling, occasionally appear as monocytes infiltrate tissues outside the bone marrow. Some patients also notice easy bruising or unusual bleeding, reflecting low platelet counts or platelet dysfunction.

Diagnosing CMML

The diagnosis rests on a few concrete criteria. Updated guidelines require sustained peripheral blood monocytosis lasting at least three months, with an absolute monocyte count of 0.5 × 10⁹/L or higher and monocytes making up at least 10 percent of the white blood cell differential. A bone marrow biopsy needs to show consistent morphologic changes, and blasts (including promonocytes) must be below 20 percent in both the blood and marrow. Critically, there also needs to be cytogenetic or molecular evidence that the monocyte expansion is clonal, meaning driven by a genetic mutation rather than a reaction to infection or inflammation.²

That last point matters because monocytosis is common and usually harmless. Chronic infections, autoimmune flares, and other myeloproliferative neoplasms can all push monocyte counts up. One of the more useful diagnostic tools is flow cytometry, which looks at the proportions of monocyte subtypes in the blood. In CMML, a disproportionately high fraction of monocytes are the “classical” type (CD14-positive, CD16-negative). Using a cutoff of more than 94 percent classical monocytes identifies CMML with about 90 percent sensitivity and 96 percent specificity, making it a strong way to distinguish CMML from reactive monocytosis or other myeloproliferative diseases that happen to have high monocyte counts.³

Genomic studies have also revealed that cases sitting right on the diagnostic borderline, with monocyte counts that barely qualify, are biologically mixed. Some of those borderline cases carry mutation patterns (like co-mutations in TET2 and SRSF2) that look very much like true CMML, while others carry mutations more typical of myelodysplastic syndromes and may be better classified that way regardless of monocyte numbers.⁴ This ongoing reclassification effort reflects how much the field’s understanding of CMML has shifted as molecular testing has become routine.

The Two Subtypes and Why They Matter

CMML is divided into a myelodysplastic (MD) form and a myeloproliferative (MP) form based on the white blood cell count at diagnosis. The dividing line is 13 × 10⁹/L: patients below that threshold are classified as MD-CMML, those above as MP-CMML.⁵ The distinction is not just academic. The two forms look and behave differently in ways that affect how doctors manage them.

MP-CMML patients tend to present with a more aggressive-looking picture: larger spleens, higher LDH levels (a marker of cell turnover), and increased bone marrow cellularity.⁶ Males are overrepresented in this group. In one study of 158 patients, splenomegaly was present in 54 percent of MP-CMML cases compared with 30 percent in the MD group.⁷ Median survival tended to be shorter for the proliferative type, and gene mutation analysis suggests the two subtypes respond to different molecular drivers: in the MD form, the number of mutated pathways influenced survival, while in the MP form, only RUNX1 mutations had a clear prognostic impact.⁵

The Genetic Landscape

One of the defining discoveries in CMML over the past two decades is how heavily the disease is shaped by somatic gene mutations. Up to 90 percent of patients carry at least one, and the three most frequently mutated genes are TET2, SRSF2, and ASXL1.⁸ Chromosomal abnormalities, which are a separate category from point mutations, show up in roughly 30 percent of cases.

Not all mutations carry equal weight. ASXL1 mutations have been consistently linked to worse survival across multiple studies. In one cohort of 146 patients, ASXL1 mutations roughly doubled the risk of death after adjusting for other factors.⁹ SRSF2 mutations, present in about a third to nearly half of CMML patients depending on the study, frequently co-occur with TET2 mutations but appear to be mutually exclusive with EZH2 mutations, hinting at distinct biological pathways.¹⁰ The disease’s molecular evolution follows a recognizable sequence: mutations in epigenetic regulators (like TET2) tend to appear early, with spliceosome mutations (like SRSF2) and signaling mutations accumulating later as the disease progresses toward acute leukemia.⁴

Single-cell studies have further revealed that the bone marrow progenitor cells in CMML can follow distinct differentiation trajectories. One pattern, characterized by inflammatory monocyte-biased progenitors and depletion of normal stem cells, is associated with worse clinical outcomes.¹¹ This kind of granular biology is increasingly shaping how doctors think about risk, moving beyond simple blast counts and blood values.

Predicting How the Disease Will Behave

Given CMML’s variability, clinicians rely on scoring systems to estimate prognosis and guide treatment decisions. The CMML-specific prognostic scoring system (CPSS) was developed specifically for this disease and has been validated against more general scoring tools. In head-to-head comparisons, the CPSS outperformed alternatives in predicting both overall survival and the risk of transformation to acute leukemia.¹²

An updated version, the CPSS-Mol, incorporates genetic data alongside clinical variables. It uses mutations in RUNX1, NRAS, SETBP1, and ASXL1, along with cytogenetic findings, transfusion dependence, white blood cell count, and marrow blast percentage, to sort patients into four risk groups. The range of outcomes is dramatic: the lowest-risk group had median survival beyond 12 years, while the highest-risk group had a median of about 18 months. The cumulative risk of the disease transforming into acute myeloid leukemia ranged from essentially zero in the lowest group to nearly 50 percent at four years in the highest.¹³ That kind of spread underscores why a CMML diagnosis means very different things for different people.

Current Treatment Options

Treatment for CMML is tailored to the subtype, symptoms, and risk category. There is no one-size-fits-all approach, and for lower-risk patients with minimal symptoms, watchful waiting with regular monitoring is a legitimate strategy. When treatment is needed, the options fall into a few main categories.

Hypomethylating Agents

The backbone of drug therapy for CMML is hypomethylating agents (HMAs), primarily azacitidine and decitabine. These drugs work by reversing some of the abnormal DNA methylation patterns that drive the disease. Meta-analyses pooling data from hundreds of CMML patients have found an overall response rate in the range of 43 to 50 percent.¹⁴¹⁵ Complete responses are less common, occurring in roughly one in five patients. The two drugs perform similarly for overall response, though decitabine has shown higher rates of marrow complete response and transfusion independence in some analyses.¹⁵

The trade-off is toxicity. HMAs suppress blood counts further before they improve them. Severe thrombocytopenia (dangerously low platelets) occurs in about a fifth of treated patients, and significant anemia and neutropenia are almost as common.¹⁴ That means the early weeks and months of therapy require close monitoring, and patients need to be well enough to tolerate a temporary worsening of their blood counts before they get better.

Hydroxyurea for Cytoreduction

For patients with the proliferative subtype who have high white cell counts or a bulky spleen but relatively low blast counts, hydroxyurea remains the standard cytoreductive drug. It helps control cell counts and shrink the spleen, improving symptoms like abdominal discomfort and early satiety.¹⁶ Hydroxyurea does not change the disease’s long-term trajectory the way HMAs or transplant might, but it can substantially improve day-to-day quality of life.

Stem Cell Transplant

Allogeneic stem cell transplant is the only treatment with curative potential. It is typically reserved for younger, fitter patients in higher-risk categories, because the procedure itself carries substantial risk. In one series of 33 patients who received myeloablative conditioning (the most intensive type of transplant preparation), five-year overall survival was 58 percent and progression-free survival was 55 percent. The relapse rate at five years was 15 percent, but non-relapse mortality, meaning death from transplant complications rather than the disease, was 30 percent.¹⁷ That risk-benefit equation is why transplant decisions require careful discussion between patients and their transplant teams.

The Link to Autoimmune and Inflammatory Disease

One of the more underappreciated aspects of CMML is how often it overlaps with autoimmune and systemic inflammatory conditions. Roughly 20 percent of patients with CMML have an associated autoimmune or inflammatory disease, a rate that is clearly elevated above the background population.¹⁸ These conditions include vasculitis, connective tissue diseases, relapsing polychondritis, seronegative arthritis, and immune-related platelet destruction.¹⁹

The chicken-or-egg question is real. Sometimes the autoimmune condition is diagnosed first, and CMML is found later during workup for unexplained blood count abnormalities. Other times the two are discovered simultaneously. Steroids are the first-line treatment for the inflammatory component, and they work well initially, producing responses in roughly 85 percent of cases. But about half of patients become steroid-dependent or relapse when the steroids are tapered.¹ Reassuringly, having an autoimmune condition alongside CMML does not appear to worsen the cancer’s prognosis.¹⁹

Cardiovascular Risk

Persistently elevated monocytes are not just a diagnostic marker; they appear to have biological consequences beyond the bone marrow. Monocytes play a central role in the inflammation that drives atherosclerosis, and there is accumulating evidence that CMML patients face an increased rate of cardiovascular events. One study found a more than twofold increase in cardiovascular events among CMML patients compared with matched controls.²⁰ While this finding needs further confirmation, it raises the possibility that managing traditional cardiovascular risk factors, like blood pressure and cholesterol, deserves extra attention in people with CMML.

When CMML Transforms to Acute Leukemia

The most feared complication of CMML is progression to acute myeloid leukemia (AML). This transformation happens when blast counts exceed 20 percent, and it dramatically worsens the outlook. Risk factors for this transition include younger age at CMML diagnosis and prior chemotherapy exposure.²¹ The molecular scoring systems described earlier are partly built to predict this risk: in the highest CPSS-Mol category, nearly half of patients transformed within four years.¹³

Once AML has developed from CMML, treatment becomes more difficult. The leukemia cells carry the full mutational burden accumulated during the CMML phase, and outcomes with standard AML chemotherapy are generally poor. This is one reason clinicians may push for stem cell transplant earlier in high-risk patients rather than waiting for transformation.

CMML in Younger Adults

CMML is overwhelmingly a disease of older adults, with a median age at diagnosis in the early 70s. But it does occur in younger people, and when it does, it looks somewhat different. Patients diagnosed at age 50 or younger present more often with splenomegaly (59 percent versus 11 percent in older patients) and hepatomegaly (25 percent versus 2 percent). Their mutation profiles are also distinct: younger patients are less likely to carry TET2 and SRSF2 mutations, the two most common mutations in older CMML, and more likely to harbor PTPN11 mutations.²²

Despite these differences in presentation and biology, overall survival and leukemia-free survival did not differ significantly between younger and older groups in one large analysis.²² That said, younger patients are often better candidates for stem cell transplant, which could shift their long-term outcomes favorably if they fall into a higher-risk category.

Emerging Therapies and the Push for Dedicated Trials

For decades, CMML was grouped with myelodysplastic syndromes in clinical trials, meaning treatments were tested on mixed populations and CMML-specific conclusions were hard to draw. That is starting to change. More than 25 agents are now being evaluated in early-phase trials for CMML and related myeloid cancers, often layered on top of an HMA backbone.²³

Among the more promising candidates are ruxolitinib (a JAK inhibitor already used in other myeloproliferative diseases), lenzilumab (an antibody targeting the inflammatory cytokine GM-CSF), sotatercept (which promotes red blood cell maturation and could address anemia), and tagraxofusp (which targets a receptor commonly found on CMML cells). The consensus forming among researchers is that effective CMML therapy will probably need to hit multiple pathways at once, rather than relying on any single drug.²³ That kind of combination approach is difficult to test without CMML-specific trials, which is one reason the field is increasingly calling for them.

Patient-reported outcome measures are also getting more attention. CMML causes a wide spectrum of physical and psychosocial effects, and standard quality-of-life questionnaires designed for more common cancers miss some of the symptoms that matter most to people living with this disease.²⁴ Work is underway to develop disease-specific instruments that better capture the fatigue, infection burden, and treatment side effects that patients actually experience, so that clinical trials measure not just whether the blood counts improve but whether people feel better.²⁵